X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) and Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Volatility and Risk
X4 Pharmaceuticals has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Biorestorative Therapies has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
Profitability
This table compares X4 Pharmaceuticals and Biorestorative Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| X4 Pharmaceuticals | -568.80% | -63.05% | -36.89% |
| Biorestorative Therapies | -3,088.27% | -508.42% | -230.94% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for X4 Pharmaceuticals and Biorestorative Therapies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| X4 Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| Biorestorative Therapies | 1 | 1 | 0 | 0 | 1.50 |
X4 Pharmaceuticals currently has a consensus target price of $11.25, suggesting a potential upside of 251.56%. Given X4 Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe X4 Pharmaceuticals is more favorable than Biorestorative Therapies.
Earnings & Valuation
This table compares X4 Pharmaceuticals and Biorestorative Therapies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| X4 Pharmaceuticals | $35.11 million | 9.04 | -$79.20 million | ($1.20) | -2.67 |
| Biorestorative Therapies | $357,870.00 | 5.79 | -$14.24 million | ($21.40) | -0.07 |
Biorestorative Therapies has lower revenue, but higher earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
X4 Pharmaceuticals beats Biorestorative Therapies on 10 of the 14 factors compared between the two stocks.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
About Biorestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
